adalimumab,secukinumab
novartis,abbvie
['secukinumab', 'adalimumab', 'axspa']
interested in this late-breaker, comparative study of secukinumab (il17) vs adalimumab (tnf) in axspa no difference in radiographic progression at 1 year - in line with my perception of relative equality for these treatments need long term data! #acr22 abstr#l15 
MCW Rheumatologist | Internal Medicine APD | Rheumatology APD | Med Dir Vasculitis Program | Host, EBRheum Podcast | https://t.co/o4nOnziCiM | Newsletter: